Press releases

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

The Boost-ID project was selected and financed under the France Relance plan The installation and qualification, in DEINOVE's premises in...

Favorable opinion of the DSMB and continuation of the Phase II of of DNV3837 in the treatment of Clostridioides difficile infection ◦...

The extension of the clinical trial in Canada will add 5 new sites to those already active in the United States and accelerate patient...

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...

The AGIR program, supported by the Investments for the Future Program, has allowed DEINOVE and the Charles Viollette Institute to develop...

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...

The DSMB* considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The...

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...